Literature DB >> 17952700

Surgery for digestive malignancies in patients with psychiatric disorders.

Nobuyoshi Aoyanagi1, Ichiro Iizuka, Minoru Watanabe.   

Abstract

BACKGROUND: The psychiatric population has been reported to be accompanied with a higher morbidity and mortality in several situations. However, little is known about the effect of co-morbid psychiatric disorders on surgical risk during major digestive surgery for malignancies. Our purpose in the present study, therefore, was to evaluate the impact of co-morbid psychiatric disorders on the outcome of surgery for digestive malignancies.
METHODS: We retrospectively reviewed medical records of 568 consecutive patients who underwent hepatectomies, gastrectomies, or colorectal resections between June 1998 and May 2006. Of these, 86 patients had psychiatric disorders (disorder group: DG) and the remaining 482 patients did not (non-disorder group: NG). Postoperative parameters including morbidity, mortality, length of postoperative hospital stay in the surgical ward, and the incidence of psychiatric disorder-associated problems were assessed.
RESULTS: Overall, there was 1 patient who died within 30 days in hospital in the DG and 2 patient deaths in the NG. Thirty complications developed in 24 patients of the DG, whereas 138 complications developed in 129 patients of the NG. There was no significant difference in the morbidity or mortality rate between the two groups. The length of the postoperative hospital stay was also similar between the two groups, and the incidence of psychiatric disorder-associated postoperative problems was about ten times higher in the DG than in the NG.
CONCLUSIONS: Patients with psychiatric disorders are not accompanied with excess surgical risk during major surgery for digestive malignancies as compared to patients without psychiatric disorders.

Entities:  

Mesh:

Year:  2007        PMID: 17952700     DOI: 10.1007/s00268-007-9267-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.282


  8 in total

Review 1.  Antipsychotic-induced venous thromboembolism: a review of the evidence.

Authors:  Staffan Hägg; Olav Spigset
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans.

Authors:  A L Klatsky; M A Armstrong; J Poggi
Journal:  Am J Cardiol       Date:  2000-06-01       Impact factor: 2.778

3.  Differences in perioperative coagulation between Japanese and other ethnic groups undergoing laparoscopic cholecystectomy.

Authors:  M Iwade; K Iwade; M Nomura; M Ozaki
Journal:  Surg Endosc       Date:  2003-10-28       Impact factor: 4.584

4.  Postoperative complications in patients with disabling psychiatric illnesses or intellectual handicaps. A case-controlled, retrospective analysis.

Authors:  B S Cutler; M P Fink
Journal:  Arch Surg       Date:  1990-11

5.  Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study.

Authors:  G L Zornberg; H Jick
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

6.  Mortality in patients with schizophrenia, mania, depression and surgical conditions. A comparison with general population mortality.

Authors:  M T Tsuang; R F Woolson
Journal:  Br J Psychiatry       Date:  1977-02       Impact factor: 9.319

7.  Adverse events during medical and surgical hospitalizations for persons with schizophrenia.

Authors:  Gail L Daumit; Peter J Pronovost; Christopher B Anthony; Eliseo Guallar; Donald M Steinwachs; Daniel E Ford
Journal:  Arch Gen Psychiatry       Date:  2006-03

8.  Adverse surgical outcomes among patients with cognitive impairments.

Authors:  G M Bernstein; S K Offenbartl
Journal:  Am Surg       Date:  1991-11       Impact factor: 0.688

  8 in total
  1 in total

1.  Surgical management of colorectal cancer in patients with psychiatric disorders.

Authors:  Naoki Hashimoto; Naoki Isaka; Yoshiya Ishizawa; Toshihito Mitsui; Mutsuo Sasaki
Journal:  Surg Today       Date:  2009-04-30       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.